Abstract
Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Clinical Trials as Topic
-
Enzyme Inhibitors / pharmacology*
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Leukemia / drug therapy
-
Leukemia / enzymology
-
Proto-Oncogene Proteins / antagonists & inhibitors*
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
-
fms-Like Tyrosine Kinase 3
Substances
-
Enzyme Inhibitors
-
Proto-Oncogene Proteins
-
FLT3 protein, human
-
Receptor Protein-Tyrosine Kinases
-
fms-Like Tyrosine Kinase 3